For relapsed/refractory AML patients with a targetable mutation such as FLT3-ITD or IDH1/2, administering small-molecule inhibitors may represent an alternative to conventional salvage chemotherapy. This evidence concerns the gene IDH1 and acute myeloid leukemia.